Sugi Predict

Sugi Predict / Compounds / SCHEMBL244272

SCHEMBL244272

SCHEMBL244272

CC(C)C[C@@H](C(=O)O)N(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RNPEP Q9H4A4 1/20 0.52
▸ SLC7A5 Q01650 1/20 0.46
▸ CPA1 P15085 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.40
▸ SLC1A3 P43003 2/20 0.40
▸ SLC1A2 P43004 2/20 0.40
▸ MAPT P10636 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SLC1A1 P43005 1/20 0.38
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ NR4A2 P43354 1/20 0.37
▸ CACNA2D1 P54289 2/20 0.35
▸ CACNB3 P54284 1/20 0.35
▸ CACNA1C Q13936 1/20 0.35
▸ PGR P06401 1/20 0.35
▸ ADRA1A P35348 1/20 0.35
▸ HTR2B P41595 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14890257 1.00 RNPEP (0.52) RNPEPSLC7A5CPA1ALDH1A1SLC1A3
SCHEMBL244271 1.00 RNPEP (0.52) RNPEPSLC7A5CPA1ALDH1A1SLC1A3
Hydrochloric Acid SCHEMBL3050176 0.98 RNPEP (0.50) RNPEPSLC7A5CPA1ALDH1A1SLC1A3
SCHEMBL11161410 0.84 RNPEP (0.46) RNPEPSLC7A5CPA1ALDH1A1SLC1A3
SCHEMBL23182436 0.84 RNPEP (0.46) RNPEPSLC7A5CPA1ALDH1A1SLC1A3
SCHEMBL3047828 0.83 RNPEP (0.44) RNPEPSLC7A5CPA1ALDH1A1SLC1A3
SCHEMBL3047827 0.83 RNPEP (0.44) RNPEPSLC7A5CPA1ALDH1A1SLC1A3
SCHEMBL7365108 0.81 RNPEP (0.43) RNPEPSLC7A5CPA1ALDH1A1SLC1A3
SCHEMBL18125957 0.81 RNPEP (0.43) RNPEPSLC7A5CPA1ALDH1A1SLC1A3
SCHEMBL7368232 0.81 RNPEP (0.43) RNPEPSLC7A5CPA1ALDH1A1SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025101947-A1 MULTIPLEXED TARGETED PEPTIDE QUANTITATION Astrin Biosciences, Inc. (US) 2025-05-15 — — WO claimed
US-20240036055-A1 Multiplexed DiLeu-Biotin-Azide (DBA) Tag Enabled Isobaric Tandem Orthogonal Proteolysis Activity-Based Protein Profiling (isoBOP-ABPP) Platform For High-Throughput Quantitative Pan-PTM Analysis WISCONSIN ALUMNI RESEARCH FOUNDATION 2024-02-01 — — US claimed
CN-110950774-B Protein quantitative marking reagent and preparation method and application thereof 北京大学 2021-04-13 — — CN claimed
CN-112135812-A Ketamine derivatives and pharmaceutical compositions thereof 凯瑞康宁生物工程（武汉）有限公司 2020-12-25 — — CN claimed
CN-110950774-A Protein quantitative marking reagent and preparation method and application thereof 北京大学 2020-04-03 — — CN claimed
US-20160244484-A1 ANTI-INFLAMMATORY TRIPEPTIDES DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) 2016-08-25 — — US claimed
EP-3049428-A1 ANTI-INFLAMMATORY TRIPEPTIDES Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) 2016-08-03 — — EP claimed
CN-105636975-A Anti-inflammatory tripeptides DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL 2016-06-01 — — CN claimed
WO-2015040235-A1 ANTI-INFLAMMATORY TRIPEPTIDES DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) 2015-03-26 — — WO claimed
EP-2477962-A1 PRODRUGS OF GUANFACINE Shire LLC (US) 2012-07-25 — — EP claimed
US-6458781-B1 BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS WARNER-LAMBERT COMPANY 2002-10-01 — — US claimed
US-6362174-B1 ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS WARNER-LAMBERT COMPANY 2002-03-26 — — US claimed
US-20020028801-A1 Reduced dipeptide analogues as calcium channel antagonitsts RAFFERTY MICHAEL FRANCIS (US) 2002-03-07 — — US claimed
US-6316440-B1 TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY WARNER-LAMBERT COMPANY 2001-11-13 — — US claimed
US-20010023249-A1 Calcium channel blockers HU LAIN-YEN (US) 2001-09-20 — — US claimed
US-6117841-A USED TO TREAT STROKE, CEREBRAL ISCHEMIA, PAIN, HEAD TRAUMA OR EPILEPSY WARNER-LAMBERT COMPANY (US) 2000-09-12 — — US claimed
WO-2000006559-A1 REDUCED DIPEPTIDE ANALOGUES AS CALCIUM CHANNEL ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2000-02-10 — — WO claimed
WO-1999055688-A1 SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1999-11-04 — — WO claimed
WO-1999007689-A1 ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS WARNER-LAMBERT COMPANY (US) 1999-02-18 — — WO claimed
WO-1998054123-A1 SUBSTITUTED PEPTIDYLAMINE CALCIUM CHANNEL BLOCKERS WARNER-LAMBERT COMPANY (US) 1998-12-03 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244484-A1 ANTI-INFLAMMATORY TRIPEPTIDES VIP, TNF, ENPEP RNPEP 85/4885SLC7A5 1859/4885CPA1 38/4885
US-20010023249-A1 Calcium channel blockers CACNA1I, CACNA1B, CACNA1G RNPEP 4072/4885SLC7A5 3089/4885CPA1 682/4885
US-20020028801-A1 Reduced dipeptide analogues as calcium channel antagonitsts CACNA1E, RYR1, CACNA1B RNPEP 1628/4885SLC7A5 1111/4885CPA1 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.